CAS号:1878109-26-2英文名:L-Proline,4-[[3-[(2E)-1,1-difluoro-4-hydroxy-2-buten-1-yl]-2-quinoxalinyl]oxy]-,methylester,(4R)-英文别名:L-Proline,4-[[3-[(2E)-1,1-difluoro-4-hydroxy-2-buten-1-yl]-2-quChemicalbookinoxalinyl]oxy]-,methylester,(4R)-中文名:L-PROLINE,4-[[3-[(2E)-1,1-DIFLUORO-4-HYDROXY-2-BUTEN-1-YL]-2-QUINOXALINYL]OXY]-,METHYLESTER,(4R)-中文别名:CBNumber:CB311802861分子式:C18H19F2N3O4分子量:379.36
*The following content is generated by AI and is for reference only.
L-Proline, 4-[[3-[(2E)-1,1-difluoro-4-hydroxy-2-buten-1-yl]-2-quinoxalinyl]oxy]-, methyl ester, (4R) is a sophisticated chiral organic molecule belonging to the class of quinoxaline-based proline derivatives. This compound features a complex structural architecture combining a rigid quinoxaline core with a functionalized difluorobutenyl side chain and a stereodefined L-proline methyl ester moiety. The presence of the (4R) configuration indicates specific stereochemistry at the proline ring, which is critical for its potential biological activity and interaction with chiral targets. While specific commercial CAS registry numbers may vary depending on the exact synthetic batch or proprietary classification, this structure represents a specialized intermediate often utilized in advanced medicinal chemistry research.
The primary application of such molecules lies in the field of pharmaceutical development, particularly in the design of enzyme inhibitors or receptor modulators. The quinoxaline scaffold is well-known for its pharmacological versatility, exhibiting antibacterial, antifungal, and anticancer properties in various contexts. By integrating a fluorinated alkene chain, researchers aim to enhance metabolic stability and lipophilicity, thereby improving bioavailability and membrane permeability. Furthermore, the chiral L-proline component serves as a crucial element for inducing asymmetric catalysis or acting as a lead structure for developing potent therapeutic agents targeting specific protein kinases or G-protein coupled receptors (GPCRs).
In laboratory settings, this compound is typically employed as a building block for synthesizing larger, more complex heterocyclic systems. Its unique combination of electron-withdrawing fluorine atoms and hydrogen-bonding hydroxyl groups allows for fine-tuning molecular interactions within biological environments. Although not yet a widely marketed drug candidate, it exemplifies modern strategies in rational drug design where precise stereochemical control and halogenation are leveraged to optimize potency and selectivity. Researchers utilize high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) spectroscopy to characterize purity and confirm the (4R) configuration during synthesis. As the demand for novel antimicrobial and anticancer therapies grows, compounds of this nature continue to play a pivotal role in preclinical studies, offering promising avenues for future clinical applications in treating resistant infections or malignancies.
![L-Proline, 4-[[3-[(2E)-1,1-difluoro-4-hydroxy-2-buten-1-yl]-2-quinoxalinyl]oxy]-, methyl ester, (4R)](https://eimg.pharmasources.com/image/20250225/oPV8rkEBYOxdgWcuZAnfd6WGzQNuOBI58BWsNtNn.png)
(All Rights Reserved)
![8-Oxa-1,3-diazaspiro[4.5]decane-2,4-dione](https://eimg.pharmasources.com/image/product/20250403/60fa7223d5a34f24138486ceea0ffb15jpg)
![6,8-Dioxo-5,7-diazaspiro[3.4]octane-2-carboxylic acid](https://eimg.pharmasources.com/image/product/20250403/02effeb5a7639bc84ff1f3add3c0c64fjpg)
![8,16-Diazadispiro[6.1.6.2]heptadecan-17-one](https://eimg.pharmasources.com/image/product/20250403/ca91cba8b87e53fc879f8d8764873a40jpg)
